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Next generation sequencing (NGS), which became widely 
used during the last decade, has enabled incredible progress 
in genetic diagnostics of many inherited diseases. In the era 
of precision medicine, NGS is considered a gold standard 
for the diagnosis of Mendelian diseases thanks to its high 
throughput, cost effectiveness and high accuracy. This 
opens avenues for personalised medicine, including tailored 
treatment strategies and disease prognosis. 
A recent paper published by J Rao, X Liu, J Mao and 
colleagues for “Internet Plus” Nephrology Alliance of 
National Center for Children’s Care presents a genetic 
spectrum of renal diseases in a national cohort of 1,001 
Chinese children. Patients were recruited to the Chinese 
Children Genetic Kidney Disease Database (CCGKDD), 
which is the largest national multicentre registration 
system for the genetic diagnosis of renal disease. Little 
is known about the genetic spectrum of renal disease in 
paediatric patients in China. Thus, the CCGKDD cohort 
provides a unique opportunity to establish the mutation 
rate in young renal patients in this country. Around 30% of 
chronic kidney disease (CKD), with onset <25 years, can be 
attributed to a genetic cause. There is, however, a substantial 
variability between the reported frequency of monogenic 
cases depending on the underlying phenotypes included in 
the studies (1). The four most common diagnostic groups 
for early onset (<25 years) CKD are congenital anomalies 
of the kidneys and urinary tract (CAKUT), steroid resistant 
nephrotic syndrome (SRNS), chronic glomerulonephritis 
and renal cystic ciliopathies. Two thirds of early-onset CKD 
are due to those 4 subgroups and over 200 genes have been 
found to cause early onset CKD when mutated (2).
In the CCGKDD cohort, genetic diagnosis was 
confirmed in 42.1% of patients with 60.7% of those having 
a causative mutation in 1 of 15 the commonest genes. 
The authors highlight the fact that overall, in this cohort, 
mutations were found in 106 genes. As expected, different 
diagnostic yield was found in different categories of renal 
disease, i.e., 29.1% of SRNS were found to be monogenic 
while in CAKUT 17% had a mutation. All significant 
variants authors included in the supplemental material.
Median genetic diagnostic yield for patients with 
CAKUT <18 years is 17% (1), which is not detected 
based on standard clinical evaluation. Patients having 
an unsuspected genetic disorder may be at risk of 
neurocognitive impairment and thus early recognition of 
the causative mutation can impact clinical care. Patients 
with CAKUT have variable phenotype and the disease may 
also occur in conjunction with defects in other organs thus 
anatomical classification is often ambiguous with regard 
to the primary molecular aetiology. At least 50 genes have 
been found mutated in CAKUT and when a mutation is 
found is certain genes, e.g., HNF1B and PAX2 screening 
patients for diabetes or ocular coloboma respectively may 
be advisory (3). The complex genetic basis of CAKUT 
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requires large-scale human genetic studies accompanied 
with detailed phenotypic information. Therefore, studies 
like this one by Rao et al., where 17% of CAKUT patients 
were found to have a genetic cause, significantly contribute 
to the understanding the genetic architecture and mutation 
spectrum of CAKUT.
Studies like this, highlight the differences in geographic 
distribution of patients with early onset (<2 years) of renal 
disease. In the case of this study, the proportion of younger 
patients was higher in Western and Central China than 
from the Eastern part of the country. This paper also 
presents the most frequent mutations found in each disease 
subgroup which emphasises the different allelic distribution 
in different populations. In SRNS for example, the most 
frequently mutated genes were COQ8B (also known as 
ADCK4), WT1 and NPHS1 rather than NPHS1, WT1 and 
NPHS2 seen by other groups (4,5). Interethnic differences 
are likely to influence the incidence of mutations in different 
genes. This group has also found a three times higher 
than expected incidence of mutations in NPHP3 gene, 
causing nephronophthisis. Mutations in this gene have been 
reported in patients with infantile and adolescent-onset 
but more frequently in the first one (6,7). It is therefore 
possible that the higher mutation rate may be influenced 
by the number of patients with early onset of the disease 
recruited to this study, however the average onset for the 
nephronophthisis patients is not provided. Establishing 
molecular genetic diagnosis can be particularly important 
in patients requiring renal transplant. It is known that 
patients with monogenic form of SRNS are less likely to 
have a disease recurrence post-transplant (4). However, this 
is not the case for all “nephrotic” genes and/or mutations. 
Congenital nephrotic syndrome of the Finnish type is caused 
by mutations in NPHS1. The majority of these patients 
have a homozygous truncating mutation (Fin-major) which 
results in the lack of protein nephrin and anti-nephrin 
antibodies are developed in these patients after the transplant 
leading to disease recurrence in the “new kidney” (8). 
Very rarely post-transplant recurrence has also been noted 
in patients with NPHS2, WT1 or NUP93 mutations (9,10). 
Genetic diagnosis before transplant is also extremely 
important when a related donor is considered to avoid using 
a kidney from an affected member who may not yet show 
the symptoms.
Due to the lack of treatment, SRNS is one of the most 
challenging renal conditions. However, in some patients 
supplemental medication may be possible. It is known that 
when SRNS it is caused by mutations in certain genes, 
additional treatment options seem beneficial. In this 
cohort, one of the most commonly mutated genes in the 
SRNS patients was COQ8B. COQ8B is involved in CoQ10 
biosynthesis and patients with mutations in this gene may 
benefit from coenzyme Q10 supplementation (11). It has 
been shown that, if applied early, oral supplementation of 
CoQ10 may not only reduce proteinuria but also stabilize 
kidney function in COQ nephropathies (11-13). In some 
patients with mutations in podocyte genes partial or 
complete remission may be possible when treated with 
cyclosporine A (14). 
Genetic studies on large cohorts help us to understand 
what mutations are the most frequent in different 
populations and sharing the data with others strengthens 
precise mutation classification. Therefore, data from 
this cohort is extremely valuable and helps us to better 
understand the genetic architecture of early onset kidney 
diseases in China. Detailed phenotypic information as 
well as follow-up information are also vital for correct 
genotype-phenotype correlations. One of the limitations 
of this work, noted by the authors, was that they were 
unable to investigate the details of phenotype and follow 
up information. The authors stressed that improving the 
phenotype on a genomic scale needs to be included in 
the future work on CCGKDD. Even though, the present 
cohort was not a population-based cohort of Chinese 
children, and it is possible that more severe cases were sent 
to the medical centres involved in this study, still this work 
sheds light on the genetic spectrum of paediatric renal 
disease in China.
Three approaches for genetic testing were applied 
in this study. Targeted gene sequencing (TGS) where a 
large gene panel with 2,703 genes was used, including 
263 known genes responsible for kidney disease and 
thus covering 73.1% of the priority nephropathy genes. 
Second method used was whole exome sequencing (WES) 
which was available in parallel but was performed in 
more complex cases like SRNS, CAKUT or CKD with 
unknown origin as well as patients where mutation was 
not found by TGS. The third approach used was trio-
WES which was found to be extremely helpful especially in 
renal tubular disease and renal calcinosis patients enabling 
significantly higher mutation detection rate compared to 
the first two approaches. Studies often suffer from having 
many variants of unknown significance (VUS), mainly due 
to the lack of parental DNA and thus not being able to 
confirm trans character or de novo status of a mutation. 
It is therefore somehow surprising that trio-WES didn’t 
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increase the genetic diagnostic rate in other diseases in 
this study. This could potentially be caused by differences 
in patient selection for different approaches. The authors 
acknowledge that TGS was favoured in certain patients, 
including infantile or more severe nephrotic syndrome 
where mutation rate is likely to be higher than in later onset 
or milder disease. 
WES and trio-WES data have a great potential for 
further work as it should be possible to look for novel gene 
candidates for paediatric kidney disease. It is however not 
clear whether the authors have any plans to investigate 
this, even for familial cases where no causative mutation 
was found in the known genes. Utilising WES data is 
also beneficial to detect mutations in genes that were 
not originally suspected from the clinical phenotype due 
to overlapping phenotypes/phenocopy genes. For some 
patients correct diagnosis may not be possible without 
checking other genes since multiple genes often contribute 
to a specific phenotype and/or single gene defects have 
multiple clinical presentations. For instance, mutations in 
SLC4A1 and AGXT (known to cause distal renal tubular 
acidosis and hyperoxaluria type 1 respectively) were found 
in patients with renal cystic ciliopathies instead of typical/
known genes for this condition (2). Similarly, we found an 
OCRL mutation in a patient where clinical and renal biopsy 
findings indicated glomerular disease while his brother 
received presumptive diagnosis of IgA nephropathy. The 
typical for OCRL gene mutations, Lowe syndrome or 
Dent disease, were not suspected in the siblings’ clinical 
presentation (4,15). 
Copy number variation (CNV) analysis is known to be 
challenging in WES. Deletion in NPHP1 gene, detected in 
several patients was further validated with other approaches, 
e.g., real-time PCR. Authors appreciate the limitation for 
CNV detection in this study and stress that some patients, 
where no pathogenic variant was detected, were referred for 
further whole genome sequencing.
Data sharing is important as it helps understand the 
disease and its mechanisms better. The same (or similar) 
phenotype can be caused by different genetic mutations and 
vice versa the same gene/mutation may be responsible for 
different phenotypes. Thus, sharing combined genotype 
and phenotype data is extremely important and initiatives 
like patient registries/national cohorts are pivotal in gaining 
knowledge about complex genetic disorders. Establishment 
of the CCGKDD further aids our knowledge and provides 
a great resource of mutations detected in China.
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